28127799|t|TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I/II colorectal cancer
28127799|a|A considerable number of early stage colorectal cancer (CRC) patients may develop cancer relapse or metastasis after curative surgery. Isolated tumor cells (ITC) and micrometastasis in lymph nodes (LNMM), which are undetectable by conventional pathological examination, may be one primary reason. Detection of ITC / LNMM is time-consuming and cost-ineffective, we aimed to find biomarkers in primary CRC tissues to help predicting ITC / LNMM status. We enrolled 137 node-negative patients with early stage CRC in this study. Existence of ITC / LNMM was identified by immunohistological staining with cytokeratin 20 in resected lymph nodes. Expression of transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) in primary CRC tissues was also investigated. Chi-square test was performed to reveal the correlations between ITC / LNMM and clinicopathological characteristics. Univariate and multivariate analyses were used to determine independent prognostic factors. Knock-down experiment together with proliferation and invasion assays were carried out to explore molecular mechanisms between TBL1XR1 and ITC / LNMM. 29.2% (40/137) patients were identified as ITC / LNMM positive and most of them (32/40 cases, 80%) showed high TBL1XR1 expression in primary CRC tissues. Both ITC / LNMM and TBL1XR1 expression were independent prognostic factors for disease relapse or metastasis. In vitro experiments demonstrated that TBL1XR1 can regulate the expression of VEGF-C and epithelial-mesenchymal transition proteins, thus mediate the process of lymph node metastasis. Identification of ITC / LNMM is significant in evaluating clinical outcome and guiding adjuvant chemotherapy for early stage CRC patients. TBL1XR1 overexpression in CRC tissues can serve as an efficient biomarker to predict the status of ITC / LNMM.
28127799	0	7	TBL1XR1	T103	UMLS:C1176196
28127799	17	37	isolated tumor cells	T033	UMLS:C3829491
28127799	42	57	micrometastasis	T033	UMLS:C1513276
28127799	75	89	TNM stage I/II	T170	UMLS:C1515169
28127799	90	107	colorectal cancer	T038	UMLS:C1527249
28127799	145	162	colorectal cancer	T038	UMLS:C1527249
28127799	164	167	CRC	T038	UMLS:C1527249
28127799	190	204	cancer relapse	T038	UMLS:C0699753
28127799	208	218	metastasis	T038	UMLS:C0027627
28127799	225	241	curative surgery	T058	UMLS:C1511562
28127799	243	263	Isolated tumor cells	T033	UMLS:C3829491
28127799	265	268	ITC	T033	UMLS:C3829491
28127799	274	289	micrometastasis	T033	UMLS:C1513276
28127799	293	304	lymph nodes	T017	UMLS:C0024204
28127799	306	310	LNMM	T038	UMLS:C0024232
28127799	323	335	undetectable	T201	UMLS:C3827727
28127799	352	376	pathological examination	T058	UMLS:C0582103
28127799	405	414	Detection	T058	UMLS:C1511790
28127799	418	421	ITC	T033	UMLS:C3829491
28127799	424	428	LNMM	T038	UMLS:C0024232
28127799	481	485	find	T033	UMLS:C0243095
28127799	486	496	biomarkers	T201	UMLS:C0005516
28127799	508	511	CRC	T038	UMLS:C1527249
28127799	512	519	tissues	T017	UMLS:C0040300
28127799	539	542	ITC	T033	UMLS:C3829491
28127799	545	549	LNMM	T038	UMLS:C0024232
28127799	574	587	node-negative	T033	UMLS:C0678034
28127799	614	617	CRC	T038	UMLS:C1527249
28127799	626	631	study	T062	UMLS:C0681814
28127799	646	649	ITC	T033	UMLS:C3829491
28127799	652	656	LNMM	T038	UMLS:C0024232
28127799	675	702	immunohistological staining	T058	UMLS:C0487602
28127799	708	722	cytokeratin 20	T103	UMLS:C0219510
28127799	735	746	lymph nodes	T017	UMLS:C0024204
28127799	748	758	Expression	T038	UMLS:C1171362
28127799	762	803	transducin (β)-like 1 X-linked receptor 1	T103	UMLS:C1176196
28127799	805	812	TBL1XR1	T103	UMLS:C1176196
28127799	825	828	CRC	T038	UMLS:C1527249
28127799	829	836	tissues	T017	UMLS:C0040300
28127799	860	875	Chi-square test	T170	UMLS:C0008041
28127799	925	928	ITC	T033	UMLS:C3829491
28127799	931	935	LNMM	T038	UMLS:C0024232
28127799	1049	1067	prognostic factors	T201	UMLS:C1514474
28127799	1069	1090	Knock-down experiment	T062	UMLS:C2350567
28127799	1105	1118	proliferation	T038	UMLS:C0334094
28127799	1123	1131	invasion	T038	UMLS:C2699153
28127799	1132	1138	assays	T058	UMLS:C0005507
28127799	1167	1187	molecular mechanisms	T038	UMLS:C3537153
28127799	1196	1203	TBL1XR1	T103	UMLS:C1176196
28127799	1208	1211	ITC	T033	UMLS:C3829491
28127799	1214	1218	LNMM	T038	UMLS:C0024232
28127799	1263	1266	ITC	T033	UMLS:C3829491
28127799	1269	1273	LNMM	T038	UMLS:C0024232
28127799	1274	1282	positive	T033	UMLS:C1446409
28127799	1331	1338	TBL1XR1	T103	UMLS:C1176196
28127799	1339	1349	expression	T038	UMLS:C1171362
28127799	1361	1364	CRC	T038	UMLS:C1527249
28127799	1365	1372	tissues	T017	UMLS:C0040300
28127799	1379	1382	ITC	T033	UMLS:C3829491
28127799	1385	1389	LNMM	T038	UMLS:C0024232
28127799	1394	1401	TBL1XR1	T103	UMLS:C1176196
28127799	1402	1412	expression	T038	UMLS:C1171362
28127799	1430	1448	prognostic factors	T201	UMLS:C1514474
28127799	1453	1468	disease relapse	T038	UMLS:C0277556
28127799	1472	1482	metastasis	T038	UMLS:C0027627
28127799	1493	1504	experiments	T062	UMLS:C0681814
28127799	1523	1530	TBL1XR1	T103	UMLS:C1176196
28127799	1548	1558	expression	T038	UMLS:C1171362
28127799	1562	1568	VEGF-C	T103	UMLS:C0388911
28127799	1573	1595	epithelial-mesenchymal	T017	UMLS:C1181295
28127799	1596	1615	transition proteins	T103	UMLS:C0033684
28127799	1645	1666	lymph node metastasis	T038	UMLS:C0024232
28127799	1686	1689	ITC	T033	UMLS:C3829491
28127799	1692	1696	LNMM	T038	UMLS:C0024232
28127799	1755	1776	adjuvant chemotherapy	T058	UMLS:C0085533
28127799	1793	1796	CRC	T038	UMLS:C1527249
28127799	1807	1814	TBL1XR1	T103	UMLS:C1176196
28127799	1815	1829	overexpression	T038	UMLS:C0017262
28127799	1833	1836	CRC	T038	UMLS:C1527249
28127799	1837	1844	tissues	T017	UMLS:C0040300
28127799	1871	1880	biomarker	T201	UMLS:C0005516
28127799	1906	1909	ITC	T033	UMLS:C3829491
28127799	1912	1916	LNMM	T038	UMLS:C0024232